Inventor · disambiguated record
Raghida Bukhalid
Also filed as: BUKHALID RAGHIDA · BUKHALID RAGHIDA A
8 granted patents·10 pending applications·26 citations·filing 2011–2025
84Inventor score
Top patents by PatentIndex Score
18 records- 0192US12156870B2Antibody drug conjugates comprising sting agonistsMERSANA THERAPEUTICS INC·Filed 2022·Granted Dec 3, 2024·1 cites·30 claims
- 0289US9226964B2Antibodies against epidermal growth factor receptor (EGFR) and uses thereofMERRIMACK PHARMACEUTICALS INC·Filed 2014·Granted Jan 5, 2016·9 cites·37 claims
- 0384US9044460B2Antibodies against epidermal growth factor receptor (EGFR) and uses thereofBUKHALID RAGHIDA·Filed 2011·Granted Jun 2, 2015·9 cites·12 claims
- 0482US8691231B2Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodiesBUKHALID RAGHIDA·Filed 2012·Granted Apr 8, 2014·7 cites·17 claims
- 0580US12440576B2Antibody drug conjugates comprising sting agonistsMERSANA THERAPEUTICS INC·Filed 2022·Granted Oct 14, 2025·0 cites·20 claims
- 0680US2025352662A1Antibody drug conjugates comprising sting agonistsMERSANA THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 0769US2022378749A1Antibody drug conjugates comprising sting agonistsMERSANA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 0865US2014234314A1Antibodies against epidermal growth factor receptor (egfr) and uses thereofMERRIMACK PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 0961US10072299B2Antibodies against epidermal growth factor receptor (EGFR) and uses thereofMERRIMACK PHARMACEUTICALS INC·Filed 2015·Granted Sep 11, 2018·0 cites·21 claims
- 1061US9902999B2Antibodies against epidermal growth factor receptor (EGFR) and uses thereofMERRIMACK PHARMACEUTICALS INC·Filed 2015·Granted Feb 27, 2018·0 cites·21 claims
- 1161US9885087B2Antibodies against epidermal growth factor receptor (EGFR) and uses thereofMERRIMACK PHARMACEUTICALS INC·Filed 2015·Granted Feb 6, 2018·0 cites·21 claims
- 1261US2014170668A1Monoclonal and oligoclonal anti-egfr antibodies for use in the treatment of tumors expressing predominantly high affinity egfr ligands or tumors expressing predominantly low affinity egfr ligandsMERRIMACK PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 1360US2023398229A1Antibody drug conjugates comprising sting agonists, combinations and methods of useMERSANA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1459US2017356049A1Monoclonal and oligoclonal anti-egfr antibodies for use in the treatment of tumors expressing predominantly high affinity egfr ligands or tumors expressing predominantly low affinity egfr ligandsMERRIMACK PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 1555US2016083800A1Monoclonal and oligoclonal anti-egfr antibodies for use in the treatment of tumors expressing predominantly high affinity egfr ligands or tumors expressing predominantly low affinity egfr ligandsMERRIMACK PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 1647US2015368361A1Antibodies against epidermal growth factor receptor (egfr) and uses thereofMERRIMACK PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 1746US2016002339A1Antibodies against epidermal growth factor receptor (egfr) and uses thereofMERRIMACK PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 1842US2017314079A1Antibodies against epidermal growth factor receptor (egfr) and uses thereofMERRIMACK PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Raghida Bukhalid files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →